Assuming that we can group breast cancer patients according to the tumour cells’ responses to TGFβ, and evaluate the associations between the expression levels of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 and patients’ clinical outcomes such as overall and relapse-free survival in each group using Cox proportional hazards regression model, then we should expect negative log hazard ratios for type 1 tumours, log HRs of zero for type 2 tumours and positive log HRs for type 3 tumours, respectively. The gene discussed is TGFB3; the disease is breast cancer.